Oral delivery of MOMIPP lipid nanoparticles for methuosis-induced cancer chemotherapy
Nanoscale · 2025 · 17 (7) · 4082-4098
DOI: 10.1039/d4nr04044a ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanoscale, 2025. Verfasst von Zeyuan Mao und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. chaigh@mail.sysu.edu.cn. Hauptthemen laut MEDLINE: Nanoparticles, Antineoplastic Agents, Indoles, Lipids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, State Key Laboratory of Respiratory Disease.
Themen: Onkologische Pflege
Abstract (Originalsprache)
MOMIPP-SEDDS increased the relative bioavailability by 19.98-fold and achieved favorable tumor inhibition. Clear evidence of methuosis in the tumor tissue following MOMIPP-SEDDS treatment was revealed by TEM imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. chaigh@mail.sysu.edu.cn.
- State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 51006, China.
Förderung
- Fundamental Research Funds for the Central Universities
- State Key Laboratory of Respiratory Disease
Zitieren
APA
Mao, Z., & Chai, G. (2025). Oral delivery of MOMIPP lipid nanoparticles for methuosis-induced cancer chemotherapy. Nanoscale, 17(7), 4082-4098. https://doi.org/10.1039/d4nr04044a
Vancouver
Mao Z, Chai G. Oral delivery of MOMIPP lipid nanoparticles for methuosis-induced cancer chemotherapy. Nanoscale. 2025;17(7):4082-4098. doi:10.1039/d4nr04044a
BibTeX
@article{Mao2025,
author = {Mao, Zeyuan and Chai, Guihong},
title = {Oral delivery of MOMIPP lipid nanoparticles for methuosis-induced cancer chemotherapy},
journal = {Nanoscale},
year = {2025},
volume = {17},
number = {7},
pages = {4082--4098},
doi = {10.1039/d4nr04044a}
}
EUVIMED